Dr. Yost is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
25 Michigan St Suite 3100
MC 012
Grand Rapids, MI 49503Phone+1 616-391-1230
Education & Training
- Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989
- Corewell Health – Grand Rapids/Michigan State UniversityResidency, Internal Medicine, 1983 - 1987
- University of Michigan Medical SchoolClass of 1983
Certifications & Licensure
- MI State Medical License 1989 - 2026
- TN State Medical License 1988 - 1995
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013
Clinical Trials
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
- Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
- Join now to see all
Publications & Presentations
PubMed
- 220 citationsNeoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost
The New England Journal of Medicine. 2023-03-02 - 477 citationsMinimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patientsKathleen J. Yost, David T. Eton, Sofia F. Garcia, David Cella
Journal of Clinical Epidemiology. 2011-05-01 - 31 citationsPhase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).John D. Hainsworth, Kevin P. Becker, Tarek Mekhail, Sajeel A. Chowdhary, Janice Faulkner Eakle
Journal of Neuro-Oncology. 2019-08-07
Grant Support
- Grand Rapids Clinical Oncology ProgramNational Cancer Institute2001–2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: